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Abstract  
Objective: To describe factors senior critical care nurses identify as being important to 
address when introducing Selective Digestive Tract Decontamination (SDD) in the clinical 
setting.  
Background: Critically ill patients are at risk of developing ventilator-associated pneumonia 
(VAP). SDD is one strategy shown to prevent VAP and possibly improve survival in the 
critically ill.  
Methods: We performed a secondary analysis of qualitative data obtained from 20 interviews. 
An inductive thematic analysis approach was applied to data obtained from senior critical 
care nurses during phase two of a multi-methods study.  
Results: There were four primary considerations identified that should be addressed or 
considered prior to implementation of SDD. These considerations included education of 
health care professionals, patient comfort, compatibility of SDD with existing practices, and 
cost.  
Conclusions: Despite a lack of experience with, or knowledge of SDD, nurses were able to 
articulate factors that may influence its implementation and delivery. Organizations or 
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researchers considering implementation of SDD should include nurses as key members of the 
implementation team. 
Key Words: antibiotic prophylaxis, critical illness, implementation, selective 
decontamination of the digestive tract, ventilator-associated pneumonia 
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Introduction 
Critically ill patients are at risk of developing infectious complications 
1
 because of 
increased severity of illness, poor nutritional status 
2
 and the need for invasive devices. More 
than half of patients admitted to an intensive care unit (ICU) will develop an infection, the 
majority (80%) of which are endogenous infections caused by oropharyngeal or digestive 
tract microflora present on admission. 
3 
The most common infection acquired in the ICU is 
ventilator-associated pneumonia (VAP) with at least a quarter of all ICU patients affected. 
4
 
The impact of VAP on patient outcomes is substantial. VAP is associated with prolonged 
length of ventilation, increased ICU and hospital stay, greater costs, and higher mortality. 
5
  
Selective Digestive Tract Decontamination (SDD) is a prophylactic strategy which aims to 
reduce infections and improve mortality in critically ill patients by eradicating potentially 
pathogenic microorganisms in the oropharynx and digestive tract. 
6
 SDD is a four stage 
process which includes: 1) a four day course of parenteral antibiotics to control potentially 
pathogenic microorganisms present on admission; 2) administration of non-absorbable 
antimicrobials (normally polymyxin E, tobramycin and amphotericin B) to the oral cavity and 
gastrointestinal tract; 3) continuation of standard hygiene measures to control exogenous 
infections; and 4) cultures of the throat and rectum on admission and then twice weekly to 
assess the efficacy of SDD and identify emergence of resistant bacteria. 
7,8
  
SDD, when fully implemented, has been shown to prevent VAP and, in some studies, 
improve survival. 
9,10
 The effectiveness of SDD has been demonstrated in numerous 
randomized controlled trials with results showing that SDD significantly reduces Gram-
negative microorganisms in the oropharyngeal cavity 
11
 and reduces lower airway infections 
by 72%. 
12
 Although a 2006 meta-analysis of 36 randomized controlled trials did not find 
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evidence of antimicrobial resistance, 
13
 the use of SDD in clinical practice remains low 
because of the perception that this strategy will increase the development of resistant bacteria. 
Much of the SDD research has been conducted in Europe and in clinical environments with 
already low rates of resistant bacteria such as methicillin-resistant Staphylococcus Aureus. 
14
 
Consequently clinicians who work in environments where resistant bacteria are present 
question the applicability of these data to their clinical context.   
While there are divergent views on the use of SDD as a strategy to prevent the 
development of VAP, there is strong evidence that SDD significantly reduces the number of 
lower respiratory tract infections and mortality. 
15
 Recommendations to consider using SDD 
for patients ventilated for more than 48 hours has been included in the VAP prevention 
guidelines produced by The British Society for Antimicrobial Chemotherapy 
16
 and more 
recently in the Surviving Sepsis Campaign Guidelines. 
17
 It is likely with the growing body of 
evidence for SDD, and its inclusion within well-respected and implemented clinical 
guidelines, that nurses will soon be required to deliver SDD medications to critically ill 
patients. However, most critical care nurses are unfamiliar with SDD as a strategy to prevent 
infections in the critically ill. With a large international clinical trial planned and the 
inclusion of SDD as a recommendation within the most recent Surviving Sepsis Campaign 
Guidelines, 
17
 it is likely that SDD as a strategy to prevent infection may be introduced more 
widely into practice.  
To explore why SDD has not been widely adopted in clinical practice we undertook a 
program of research to describe barriers to SDD implementation and identify what further 
evidence is required before full scale clinical implementation would be considered 
appropriate and feasible has been completed. 
18
 The, multi-methods study was undertaken in 
Canada, the United Kingdom (UK) and Australia/New Zealand (ANZ) from 2010-2012 to 
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develop an understanding of issues related to current lack of adoption of SDD and 
considerations for its implementation into clinical practice. The full study protocol has been 
published elsewhere. 
18,19
  Stage 2 of this research program was a Delphi study to identify the 
range of stakeholders’ beliefs, views and perceived barriers relating to the use of SDD. The 
aim of this paper is to describe factors senior critical care nurses identified during the first 
Delphi as being important to address when introducing SDD in the clinical setting.  
Methods 
The Delphi technique was used to identify participant’s self-reported knowledge of SDD 
as well as their beliefs, views and perceived barriers to adoption and implementation of SDD. 
The Delphi technique uses a structured, iterative process including anonymised feedback, in a 
series of sequential questionnaires or ‘rounds’. We used the Delphi technique to assess levels 
of agreement on SDD within an expert group. 
20, 21
 The first Delphi round comprised semi-
structured qualitative interviews with the interview topic guide based on the Theoretical 
Domains Framework 
22
 of clinical behavior change. The interview topic guide incorporated 
questions to elicit participants’ views on the conduct and design of SDD research (Table 1).  
One hundred and forty one participants completed the first Delphi round. Ethics approval 
was obtained from relevant institutional review boards and each participant gave informed 
consent prior to the conduct of the interviews.  
The sub study of senior nurse participants 
We conducted a secondary analysis of qualitative data collected from nurse participants 
during the first Delphi round. 
18
 This secondary analysis allowed us to explore in more detail 
factors senior critical care nurses identified as being important to address when introducing 
SDD in the clinical setting, which was not a specific focus of the first Delphi round.  We 
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included data from all nurse participants (n=20), a sample size that is similar to that reported 
for other secondary analyses of qualitative data. 
23
 The majority of participants were female 
(85%; n=17) and worked in a tertiary level ICU (80%; n=16). The mean length of ICU 
experience was 22.1 years. (Table 2). All nurse participants were employed in management 
or educational leadership roles and were responsible for implementing practice change within 
the ICU.   
We specifically analysed a subset of interviews from nurse participants in order to focus 
on a an aspect of the data which was  not specifically addressed in the primary study and to 
specifically analyse data from one participant group who had shared characteristics that 
distinguished them from the larger sample. 
23
 This secondary analysis of the data allowed us 
to explore issues nurse participants identified as important for the implementation of SDD.  
Data collection 
During the first Delphi round research teams in each geographical region conducted 
interviews by telephone. Interviews lasted 20 to 60 minutes and were recorded and 
transcribed verbatim. All identifying information was removed to maintain privacy and 
confidentiality. 
Data analysis 
In conducting this secondary analysis we employed an inductive approach 
24
 where 
detailed readings of the raw data allowed for open coding, categorisation and abstraction of 
specific concepts and themes. 25 Although the interview guide was informed by the 
Theoretical Domains Framework, 
22
 we did not use this framework in our analytic approach 
and instead allowed the themes to emerge from the interview data.  Interviews were read 
multiple times by three authors (AM, LW, LR) who each independently open coded the data. 
7 
 
Through discussion a consensus approach to abstraction allowed for identification of themes. 
Data were coded into themes using NVivo 9 software (QSR International, Doncaster, 
Australia).  
Results 
Nurse participants identified a number of factors they believed might impact the 
implementation of SDD in the clinical setting. Lack of knowledge about SDD was identified 
as an important barrier that would need to be addressed prior to implementing SDD in 
practice. Additional factors identified and thematically grouped were risk to the patient, the 
impact of SDD on nursing practice and the impact of SDD on the organization.  
Knowledge 
Of the 20 nurse participants, 15 were aware of SDD as an approach to prevent VAP. The 
level of SDD knowledge amongst participants was variable and only two participants 
explicitly referred to research about SDD. Four participants had experience in administering 
SDD although most reported a lack of SDD knowledge as being common amongst their 
colleagues. There were misconceptions regarding the rationale for SDD including the belief 
that SDD was used to “prevent gut-related infections” (UK4501) or used as “a bowel and 
gastric stimulant to…expedite the flow or the processes within the gastric system” (CA9). A 
distinction between SDD and the use of chlorhexidine for mouth care was not clear with 
some participants identifying chlorhexidine as a strategy to decontaminate the oral cavity. 
  
Knowledge of the link between SDD and VAP prevention was not clearly articulated. 
Nevertheless, understanding the rationale underpinning clinical practice was perceived as 
important with one participant commenting that nurses like “to know why they’re doing 
things…”. (CA37)  
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Risks to the patient 
All participants expressed concern about the potential for SDD to cause increased bacterial 
resistance. The participants were also concerned about the possible impact of SDD such as 
the possibility of the paste “staining the teeth” or a long term effect on tooth enamel (CA2). 
Adverse events, such as aspiration of oral paste or endotracheal tube dislodgement during 
paste application, were concerns particularly if the patient actively resisted paste application. 
 The potential discomfort for patients receiving SDD as a treatment was a key 
consideration for most nurse participants. The oral component was identified as the one 
aspect of SDD that had the potential to negatively impact patient comfort, with the 
application of paste to the oral cavity potentially uncomfortable and the taste of the oral paste 
unpleasant (CA22).  
The risk of diarrhea was also a significant concern for most participants with a perception 
that SDD might make patients more susceptible to Clostridium difficile because “… you’re 
potentially knocking out the flora in their gut, in which case they can get Clostridium, 
especially if they’ve had it before.” (CA37) Diarrhea associated with SDD could contribute to 
the development of further complications such as perianal excoriation. If the diarrhea was 
significant then fecal management systems might be used which in turn might have longer-
term consequences for patients.  
Impact on nursing practice 
Concern was raised that the number of care improvement initiatives currently in place left 
little scope for the introduction of a new practice as “people are saturated [but have] limited 
resources” and “there is so much in our face that we can’t see the wood through the trees.” 
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(ANZ212). However, the process of SDD administration was not viewed as challenging 
although some participants were conscious of the amount of time required to administer all 
SDD components and recognised that this might impact on nursing workload.  
The impact of SDD on other aspects of nursing care was a consideration for some. Regular 
mouth care was viewed as fundamental for elimination of dental plaque and prevention of 
VAP. The concern that implementation of SDD might result in regular mouth care being over 
looked prompted the suggestion that there would need to be “a lot of work to ensure that 
mouth care is still of a very high standard and it [SDD] is not instead of mouth care” 
(UK1804).  
The compatibility of SDD and enteral nutrition was raised as a potential factor that could 
influence the implementation of SDD with one participant suggesting SDD might be a 
possible “competing priority” (CA9) with enteral feeding. In addition, concerns were raised 
that food in the stomach might interfere with the SDD antibiotics. Participants also raised the 
issue of feed tolerance for some, but not all, critically ill patients and queried whether the 
gastric component of SDD administration was feasible in patients with intolerance to enteral 
feeds. For those patients where small bowel feeding was required for nutritional therapy, the 
ability to administer the gastric component of SDD was questioned if a nasogastric tube did 
not remain in place. 
Impact on the organization 
Participants perceived the most significant impact on the organization was the potential 
cost of SDD because “money is really tight” (CA31). This was a particular concern as many 
of the nurse participants were responsible for day-to-day management of ICU budgets and 
“the ones who pay for all the supplies and medications” (CA22). Additional costs associated 
with laboratory tests required for surveillance screening were considered a further economic 
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impost, especially for those ICUs where routine screening was not in place (ANZ 206). As 
few ICUs delivered SDD, the need for additional resources to educate nurses in the use of 
SDD was also identified.  
A need for balance between costs and perceived benefit was highlighted and it was 
questioned whether VAP rates were sufficiently high to warrant the introduction of SDD. 
When other strategies were already established in practice and likely to be cheaper it was 
suggested that “you should address the more cost effective, simpler approaches first” (ANZ 
201). However SDD implementation was also considered an economically sensible option if 
it resulted in improved outcomes for the patient and organization.  
Discussion 
Nurses knowledge and exposure to SDD 
SDD is one strategy shown to reduce VAP rates and mortality in critically ill, ventilated 
patients 
27
 but is not widely practiced 
28,29
 outside the European context. 
30,31
 So it is not 
surprising that few participants in this study had direct experience with SDD and this likely 
explains the variability in participants’ knowledge. Existing VAP guidelines refer to SDD as 
a treatment strategy, 
32,33,34 
 however, familiarity with, and increased exposure to, SDD is 
likely to increase now that it has been included in the most recent Surviving Sepsis Campaign 
Guidelines. 
17 
Theoretical knowledge is an important component in the implementation of 
evidence-based practice 
22 
 and for nurses both knowledge of the evidence and procedural 
knowledge are important for implementation of SDD.  
In the process of supporting nurses to develop theoretical knowledge, it is important to 
focus on the distinction between decontamination of the oropharynx with the use of topical, 
non-absorbable antibiotics that feature as a component of SDD 
12 
with the use of 
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chlorhexidine as an antiseptic 
35, 36 used in routine mouthcare. This will be particularly 
important for countries where the use of cholorhexidine is more widespread as a result of 
patient safety initiatives 
26
 that recommend oral decontamination with chlorhexidine is a key 
component of their VAP bundle.  
Patient safety and comfort issues with SDD 
Addressing concerns related to patient safety and comfort should be included in any 
implementation plan. All participants expressed concern regarding the potential for 
development of antibiotic resistance and, although debated, similar concerns are described in 
the literature and these concerns likely to contribute to low SDD adoption rates. 
30, 37, 38 There 
is limited evidence regarding SDD and acquisition of resistant organisms 
39
 and further 
research in this area is warranted.  
The potential for the antibiotic paste to stain the teeth or impact tooth enamel was 
highlighted as having potential to negatively impact the patient. The antibiotic paste used in 
the oral component of the SDD regimen contains polymyxin E, tobramycin and amphotericin 
B 
12 
which are not routinely administered orally because of poor oral absorption. 
Consequently, little is known about the effect these medications have on the oral cavity or 
tooth enamel.  
Application of antibiotic paste to the oral cavity was considered potentially unpleasant for 
patients although one participant suggested very few patients refuse the treatment. Nurses 
who have administered SDD report that as many as 56% of non-sedated patients found 
application of paste to the oropharyngeal cavity bothersome and almost half (46%) of patients 
disliked the flavour of the oral paste. 
40
 There are no data available describing patients’ 
perception of SDD administration highlighting a potential area for further research.  
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The risk of diarrhea as the result of SDD administration was a concern. There are few 
reports of increased rates of diarrhea in patients receiving SDD.  One small study of severely 
burned children (n=23) receiving SDD reported higher rates of diarrhea in the SDD group 
(P=0.003) 
41 
and diarrhea caused by Clostridium difficile is uncommon and identified in 
fewer than 0.5% of patients receiving SDD. 
9
  
Issues for nursing practice 
How the use of SDD might impact existing nursing practice was an important 
consideration. Mouth care is a well-established and important aspect of nursing practice 
42
 
shown to reduce plaque biofilm, a known source of infection. 
43
 Some participants were 
concerned that the oral component of SDD might inadvertently lead to a decreased provision 
of mouth care. This emphasizes the need for a SDD implementation plan to clearly articulate 
the importance of maintaining regular mouth care practices. Such regular mouth care practice 
might include the use of chlorhexidine 
26
 and some participants questioned the potential for 
interactions between chlorhexidine and the oral paste used in SDD. The lack of data to 
address this concern highlights an important area for further research.    
Administering SDD to patients receiving enteral nutrition was an area of practice requiring 
further clarification. One issue was the potential interaction between feeds and the enteral 
component of SDD which might increase, decrease or delay the bio-availability of antibiotics, 
however absorption of antibiotics is not intended with SDD. 
3
 The volume of the enteral 
component of SDD (10 mL suspension) 
6
 was a further consideration, particularly in relation 
to feeding tolerance however the total daily volume of enteral SDD delivered is 40 mL and 
would not significantly contribute to feeding intolerance. Current SDD protocols describe 
administration of the enteral component of SDD via a nasogastric tube 
1,9
 with no 
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recommendations for enteral SDD delivery to patients receiving small bowel feeding without 
a nasogastric tube in situ.  
The perception of an increased nursing workload associated with SDD is consistent with 
reports in the literature. 
6,40
 In the context of a group-randomized, controlled, cross-over 
multicenter study of SDD, the estimated median time to deliver the full SDD protocol was 
five minutes, two minutes longer than either standard oral care or selective oral 
decontamination alone. With administration recommended four times per day 
12
 the 
introduction of SDD could potentially impact existing nursing workload, though not 
appreciably. However, many participants described feeling burdened by the implementation 
and monitoring of new practices in ICU and the capacity to absorb more change. 
Implementing practice change requires significant effort and needs to be appropriately 
resourced to be successful. 
44
 The introduction of SDD would require a significant 
educational component for nurses and their colleagues and this can be resource intensive. 
The financial burden of SDD, including the medications, microbiological surveillance and 
increased nursing workload, is an important consideration when financial resources are 
already stretched. Estimated costs of SDD have been reported at 10€ or $13 USD per day 12 
and in patients undergoing liver transplantation estimated at $3100 USD (1997) per patient, 
inclusive of medication and surveillance cultures. 
45
 However actual costs are not clearly 
described and likely to differ by region and product availability. The true cost associated with 
SDD implementation is unknown but cost concerns should be balanced against savings 
associated with a reduction in healthcare-associated infections. 
6, 46-49
 The need for more 
complete and transparent economic analyses of SDD is required particularly as costs will 
differ by region.  
Limitations 
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The study contains certain limitations. Although we interviewed 141 participants in the 
parent study, this secondary analysis includes data from only 20 of these participants, all of 
whom were critical care nurses in leadership positions. The selection of interview data only 
from critical care nurses may have overlooked additional factors important to nursing practice 
identified by other members of the interprofessional team. In the first round of the Delphi 
study we purposefully selected nurse leaders who were positioned to contribute to decision 
making within the ICU and therefore did not accommodate the views of nurses directly 
responsible for SDD administration. While most of the nurse participants in this study had an 
awareness of SDD, only four had previous experience with its administration; therefore, the 
degree to which the issues identified in this study truly reflect the concerns of critical care 
nurses who are more familiar with SDD administration is unknown. 
Implications for future research 
Most of the research to date has focused on the clinical effectiveness of SDD as a 
treatment. There is an opportunity to add to the body of SDD literature by drawing attention 
to how such a treatment might influence patient comfort and safety.  In future clinical trials of 
SDD there are opportunities for nurse researchers to concurrently examine such issues 
including the incidence of diarrhea in patients receiving SDD, the effect of SDD paste on 
tooth enamel, and patient experience of administration of the SDD oral component. The 
interaction of existing mouthcare solutions, such as chlorhexidine, with the SDD oral paste 
also requires further research.  
Conclusions 
     The implementation of SDD in clinical practice may increase as a result of the recent 
Surviving Sepsis Campaign Guidelines including a recommendation for this preventative 
strategy. Implementation of SDD as a strategy will require a comprehensive education 
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program for nurses unfamiliar with SDD and the development of an implementation plan 
which addresses risk to the patient, the impact of SDD on nursing practice and the impact of 
SDD on the organization.  
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Table 1 Delivery of SDD to patients in the Intensive Care Unit: Delphi Round 1 Topic Guide  
Domain Core Question Possible Prompts 
Knowledge In your view, what are the 
components of SDD? 
 
What are the possible variations in these 
components?  
 
 What are the components of 
SDD as they are delivered in 
your unit? 
 
Do you know about the unit 
SDD protocol? 
What does the protocol say? 
General* Is SDD delivered in your ICU?  What would you say is the main reason? 
Motivation and 
goals 
How important is the issue of 
SDD for you? 
How does it fit with other priorities in the ICU? 
Is its priority for you related to your assessment 
of the evidence? 
Professional role 
and identity 
Do you sense whether there is 
general consensus in your 
profession about SDD? 
What is the range of views? 
 
  How does SDD fit with your own professional 
standards? 
Emotion Does anyone you work with 
have strong feelings about 
SDD? 
(If Yes) Have you got a sense why they feel 
strongly about SDD? 
Social influences Would you say that your 
opinion on providing SDD has 
been influenced by your 
colleagues?  
 
(If Yes) In what way?  
(If No) Why not? 
Behavioral 
regulation 
What else are you doing to 
prevent new infections in your 
unit? 
What would need to happen in 
order to adopt SDD in your 
Unit? 
How would implementation of the protocol be 
monitored? 
If the decision was not to adopt SDD, what 
alternative procedures might you use instead? 
 How is implementation of the 
SDD protocol monitored? 
 
Are there procedures or ways of working that 
make it easier or more efficient to deliver SDD? 
Beliefs about 
consequences 
What would be (are) the 
benefits and downsides, of 
delivering SDD over and above 
what you are doing now?  
What about the bigger picture.  What might be 
the short/medium-term benefits and downsides 
compared to longer term consequences? 
Are there consequences of using SDD in ICU 
that may affect other patients in the ICU or 
hospital? 
Skills Are there any specific skills Do you think members of your profession have 
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needed for delivering SDD? these skills? (In other words, would training be 
needed to deliver SDD?) 
Nature of the 
Behavior 
How difficult would SDD be in 
comparison to what you are 
doing already?  
Do you think the complexity is an important 
barrier to adoption? 
 Are the behaviors that make up 
SDD performed often enough to 
become routine? 
Is SDD well embedded within the daily routines 
of the unit? 
Environmental 
context and 
resources 
What additional resources 
would (does) your Unit need in 
order to deliver SDD? 
Any other resources?  
 
 
  To what extent is the delivery of SDD 
influenced by physical or resource factors? 
Beliefs about 
capabilities 
How much influence do you 
personally have over whether or 
not your Unit adopts SDD?  
Do you have responsibility for instigating 
changes? 
 How difficult or easy is it for 
you to do the things that you 
are required to do as part of 
SDD delivery? 
 
What problems have you encountered? 
What would help them? 
Decision processes How would you go about 
seeking agreement among your 
colleagues about whether or not 
to adopt SDD in your Unit?  
How about individual clinical decisions - What 
would you consider when making the clinical 
decision whether or not to administer SDD to 
an individual?  
In which patient groups would you not 
administer SDD? 
 What would you consider when 
making the clinical decision to 
administer SDD to an 
individual?  
 
In which patient groups would you not 
administer SDD? 
Further research Do you think that further 
research would settle some of 
the issues surrounding SDD? 
What type of research study do you think would 
be most informative for the future of SDD 
practice? 
Is further research ethical? Why? Or why not? 
Secondary focus 1: 
Participation in an 
effectiveness trial  
 
The purpose of this study is not 
to recruit you to a trial but if 
there was a study which 
randomised patients to a SDD 
group against a no-SDD control 
group would you be willing to 
recruit patients? 
 
Why? Or why not?  
Secondary focus 2: 
Participation in an 
implementation 
trial  
 
 
If there was a study whose aim 
was to increase adoption of 
SDD in ICUs nationwide would 
you be willing to participate?  
 
Why? Or why not?  
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Other Is there anything else that you 
want to say that you haven’t 
mentioned yet? 
What do you think is the current state of the 
evidence about SDD? 
Any other ethical matters? 
Diversity 
questions: 
What ICU do you work in? 
How many beds are there in the ICU? 
How many years’ experience do you have (within ICU/professional)? 
*For those units who do not deliver SDD 
Italicised font depicts those questions modified for participants whose ICU delivers SDD. 
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Table 2 Participant details (n=20) 
 ANZ (n=6) Canada (n=8) UK (n=6) 
Female (n) 5 6 5 
Median Age (IQR) 47 (38-51) 48 (47-52) 48 (45-49) 
Working in a 
tertiary ICU (n) 
4 4 8 
Median (IQR) 
length of ICU 
experience (years) 
24 (15-26) 20.1 (8.4) 23 (20-26) 
ANZ – Australia and New Zealand 
UK – United Kingdom 
IQR – Interquartile range 
 
